Cargando…
Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
BACKGROUND: Colchicine is an available, safe, and effective anti-inflammatory drug and has been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID-19 patients has not been thoroughly demonstrated. OBJECTIVE: To address the safety and efficacy of colchicine in hospital...
Autores principales: | Absalón-Aguilar, Abdiel, Rull-Gabayet, Marina, Pérez-Fragoso, Alfredo, Mejía-Domínguez, Nancy R., Núñez-Álvarez, Carlos, Kershenobich-Stalnikowitz, David, Sifuentes-Osornio, José, Ponce-de-León, Alfredo, González-Lara, Fernanda, Martín-Nares, Eduardo, Montesinos-Ramírez, Sharon, Ramírez-Alemón, Martha, Ramírez-Rangel, Pamela, Márquez, Manlio F., Plata-Corona, Juan Carlos, Juárez-Vega, Guillermo, Gómez-Martín, Diana, Torres-Ruiz, Jiram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577644/ https://www.ncbi.nlm.nih.gov/pubmed/34755269 http://dx.doi.org/10.1007/s11606-021-07203-8 |
Ejemplares similares
-
Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico
por: Marfil-Garza, Braulio A., et al.
Publicado: (2018) -
Redefining COVID-19 Severity and Prognosis: The Role of Clinical and Immunobiotypes
por: Torres-Ruiz, Jiram, et al.
Publicado: (2021) -
Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study
por: Rajme-López, Sandra, et al.
Publicado: (2022) -
FANSY POSTCOV: A composite clinical immunological predictive index for post‐COVID‐19 syndrome unveils distinctive features in a cohort study of mild to critical patients
por: Torres‐Ruiz, Jiram, et al.
Publicado: (2021) -
Interested, Though Not Competing
por: Snell, A. Saxon
Publicado: (1912)